Compare BioSyent, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
CAD 178 Million (Small Cap)
21.00
NA
0.00%
-0.69
21.73%
4.30
Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Dec 2025)
Net Profit:
2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.8%
0%
5.8%
6 Months
35.19%
0%
35.19%
1 Year
33.09%
0%
33.09%
2 Years
68.79%
0%
68.79%
3 Years
92.11%
0%
92.11%
4 Years
59.56%
0%
59.56%
5 Years
95.97%
0%
95.97%
BioSyent, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.72%
EBIT Growth (5y)
12.58%
EBIT to Interest (avg)
7.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.98
Tax Ratio
25.74%
Dividend Payout Ratio
25.62%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
100.69%
ROE (avg)
18.15%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
4.45
EV to EBIT
14.22
EV to EBITDA
13.17
EV to Capital Employed
9.23
EV to Sales
3.66
PEG Ratio
0.91
Dividend Yield
NA
ROCE (Latest)
64.92%
ROE (Latest)
21.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
9.70
12.20
-20.49%
Operating Profit (PBDIT) excl Other Income
2.60
3.60
-27.78%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.00
2.70
-25.93%
Operating Profit Margin (Excl OI)
247.00%
278.90%
-3.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -20.49% vs 19.61% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -25.93% vs 35.00% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
43.10
35.00
23.14%
Operating Profit (PBDIT) excl Other Income
12.20
9.20
32.61%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
9.00
7.30
23.29%
Operating Profit Margin (Excl OI)
262.80%
246.50%
1.63%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 23.14% vs 10.76% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 23.29% vs 12.31% in Dec 2024
About BioSyent, Inc. 
BioSyent, Inc.
Pharmaceuticals & Biotechnology
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Company Coordinates 
Company Details
170 Attwell Dr Suite 520 , ETOBICOKE ON : M9W 5Z5
Registrar Details






